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Whether mechanical ventilation (MV) induces neurotox-
icity that can trigger or accelerate chronic cognitive disor-
ders is controversial [1, 2]. The relationship between MV
and neurocognitive impairment—that persisted at hospital
discharge and at 1-year follow up—was first reported in
1999 in MV-treated ARDS patients [3]. Since then, several
preclinical and clinical studies have investigated the mech-
anisms, localization, and timing of brain damage induced
by MV and possible preventive/therapeutic strategies.
MV-induced brain damage: mechanisms,
localization, and timing
Alveolar stretching, PaO2/PaCO2 abnormalities, and
cytokine and chemokine expression in the lungs are
the pivotal mechanisms that possibly contribute to
MV-induced brain damage [4–9] (Table 1). Alveolar
stretching promotes the production of systemic and
cerebral mediators (cytokines, chemokines, reactive
oxygen species, microglia, and immune system activa-
tion) that lead to neuroinflammation, dopaminergic
neuronal signaling, and beta amyloid synthesis [4–9].
Relevance of MV-induced alveolar stretching in brain
damage is witnessed by production of cerebral beta-
amyloid and Alzheimer’s disease-like brain degener-
ation (cerebral amyloid β peptide accumulation, neu-
roinflammation, and blood-brain barrier dysfunction)
even after relatively “short-term MV” (after 4 h MV in
mice)—as reported in a recent study published in Crit-
ical Care [8]. The PaO2/PaCO2 abnormalities—includ-
ing hypo and hyper O2 and/or CO2 that often
represent the indication to establish MV and can per-
sist during MV—might contribute to promote neur-
onal death, cerebral oxidative stress, and changes in brain
blood flow that worsen brain damage [10, 11]. Increased
systemic inflammatory mediators produced by the lungs
during MV (“biotrauma”) have been detected in several
preclinical studies and include TNF alpha, IL6, IL10, IL1
beta, MCP1, and MIP2, which have a proven
neuroinflammatory role [4, 5, 7]. Furthermore, MV directly
triggers brain inflammation inducing cerebral expression
of proinflammatory cytokines (TNF-alpha, IL-1beta, and
IL-6) and microglia activation [6, 7, 11]. Of note, the in-
crease in some cerebral inflammatory mediators (TNF-
alpha) is proven to be higher when larger tidal volume is
applied [5]. Also, the immune system modulation has a key
role in MV-induced neuroinflammation, and in preclinical
models, an increase in Toll-like receptor 4 (TLR-4) expres-
sion (a component of the innate immune system with a
role in neuronal survival, neuroplasticity, memory, learn-
ing, and cognitive decline) has been detected in the hippo-
campus after 6 h of MV [7]. Of note, the increase in brain
TLR4 expression, and the related increase in plasma and
hippocampus cytokines (IL1beta, IL6, TNF alpha) concen-
tration, predicts the extent of memory impairment [7]. The
lung-brain vagal reflex induced by MV can also contribute
activating dopamine receptors type 2 (DRD2) in the hippo-
campus and leading to neuronal apoptosis [9].
Some evidence brought conflicting results on MV-in-
duced neurocognitive decline. While alveolar stretch
induced by MV promotes de novo synthesis of adhesion
molecules in the lung, liver, and kidneys, there is no evi-
dence of such effect in the brain [12]. Furthermore, several
of the studies that tested the impact of MV on the brain
and neurocognitive functions have limitations that make
recorded results not immediately suitable for the clinical
realm and lack to discriminate for possibly confounding
factors. Last but not the least, the histo-pathological dam-
age, especially when it occurs in the brain, does not neces-
sarily translate into a clinically detectable impairment of
neurocognitive functions. For example, a study from
Kamuf and coll showed no relationship between MV and
an increase in inflammatory mediators eventually associ-
ated with brain injury [6].
Clinical relevance of PaO2/PaCO2 abnormalities and
their impact on cognitive function in MV-treated patients
has been reported by several studies [10, 13]. Hypoxia—
frequent in patients in whom MV is indicated—has been
hypothesized to be the most relevant cause of long-term
cognitive impairment in patients with ARDS, and it is
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associated with increased mortality in patients with acute
brain damage that require MV [3, 13]. It affects neuronal
oxidative phosphorylation, and some brain areas—as the
hippocampus—result to be more vulnerable to hypoxic
damage and are keener to develop atrophy after hypoxic
events [13]. Hypercapnia—another possible indication for
MV—causes cerebral vasodilatation with consequent
increase of intracranial pressure, and it is associated with
mild cognitive impairment in MV preclinical and clinical
models [3, 13]. On the other hand, also hyperoxia—which
sometime occurs during MV—is a possible mechanism of
brain damage since it impairs cerebral autoregulation,
reduces CMRO2, and is associated with delayed visual
evoked potentials [3, 13]. Hypocapnia—a possible iatro-
genic complication of MV—induces cerebral vasoconstric-
tion, reduces cerebral compliance, and is associated with a
poorer neurological outcome in MV experimental models
[10, 13].
Monitoring and prevention of MV-induced
neurocognitive functions decline
Several strategies have been tested to prevent MV-induced
brain damage and the related neurocognitive decline; these
include neuroinflammatory scavengers, immune modula-
tion, to blunt the dopaminergic neuronal signaling with
DRD2-blockers, and lung protective ventilation strategies.
The use of scavenger receptor class A has been extensively
tested in Alzheimer disease and might play a role in the
prevention of MV-induced neurocognitive functions
decline. Immune modulation with TLR-4 antagonist has
been proven in preclinical models to effectively reduce
MV-related neuroinflammation and the extent of cognitive
disorders [7]. The use of selective DRD2-blocker (haloperi-
dol) has been successfully tested in experimental animals
and is proven to restore the activity of cell survival path-
ways in the hippocampus, potentially reducing neuronal
apoptosis [9]. Protective lung ventilation, with the use of
low tidal volume in patients hospitalized after resuscitation
for cardiac arrest, associates with better neurocognitive
outcome [14]. Optimal PaO2/PaCO2 management
correlates with better neurocognitive status in patients with
acute brain injury treated with MV [10, 13].
Conclusions
Growing preclinical and clinical evidence suggest that MV
induces harmful effects on neurocognitive functions. It is
not easy to discriminate whether these changes should be
interpreted as direct MV-induced damage or as result of
perioperative/critical care environment and preexisting
frailty. Given the importance to preserve patient’s cogni-
tive functions, we consider it necessary to define a work-
up dedicated to monitor neuroinflammation during MV
that might include neuroinflammatory scavengers,
immune modulation, DRD2-blockers, and lung “neuro-
protective” MV management. The latter should encom-
pass optimal MV setting, including low tidal volume, the
lowest FiO2 needed, to maintain—when possible—PaCO2
within normal values and to warrant the shortest MV
exposure.
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